Rallybio Corp $RLYB

What the company doesAI summary of filing

Rallybio Corp is a clinical-stage biotechnology company developing therapies for severe and rare diseases. The company's lead program, RLYB116, is a complement component 5 inhibitor in clinical development for complement dysregulation disorders; its second program, RLYB332, is a long-acting matriptase-2 antibody in preclinical development for iron overload diseases. The company is pre-revenue and generates cash through milestone payments and royalties from asset dispositions, including a $20 million payment received in 2025 from the sale of its joint venture interest in an ENPP1 inhibitor program to Recursion. Rallybio is pursuing a merger with Candid, a clinical-stage company developing T-cell engager therapeutics for autoimmune diseases, and winding down operations not needed post-merger. [10-K 2026-03-16]

Segments: RLYB116 (C5 inhibitor for complement dysregulation), RLYB332 (matriptase-2 antibody for iron overload), REV102 (ENPP1 inhibitor - divested to Recursion), AbCellera collaboration (antibody therapeutics for rare diseases)